Editas Medicine Inc

Financials

Cash from operating activities 179.84 M163.8 M177.35 M132.18 M210.28 M 179.62 M Cash from investing activities 140.52 M54.47 M114.07 M3.73 M162.15 M 169.57 M Cash from financing activities 224.12 M282.11 M1.28 M118.04 M56.03 M 78.66 M Free cash flow 172.68 M155.83 M173.23 M127.46 M201.46 M 178.53 M

Editas Medicine, Inc., is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.

EDIT

Financials

Editas Medicine Inc

ニュース

Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound?

NVO Stock Down as Rybelsus Misses Goals in 2 Alzheimer's Studies

Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline

AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo

COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know

Top 3 Genomics Stocks to Consider for Your Portfolio

Is Alto Neuroscience, Inc. (ANRO) Outperforming Other Medical Stocks This Year?

Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y

クリア・ストリート、エディタス・メディシンの目標株価を現金残高の延長により4.60ドルに引き上げ

Clear Street raises Editas Medicine stock price target to $4.60 on extended cash runway

Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates

【決算速報】エディタス・メディシン、売上高は予想を上回り、利益は予想を上回る結果に